10 slides from Evolus, Inc. Common Stock's earnings presentation, Mar 7, 2024
Slide 1: Evolysse/Estyme Filler Update
Evolysse /Estyme® Filler Update Dr. Rui Avelar, MD Chief Medical Officer and H e a d of R&D
Slide 2: Disclosures: Special Note Regarding Forward-Looking Statements
DISCLOSURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Thi s presentation contains forward-looking statements as defined under the Pri vate Securities Li tigation Reform Act of 1995. Al l statements other than statements of historical facts contained in this presentation, including s ta temen
Slide 3: Evolysse Manufacturing
EvolysseTM Manufacturing FIRST-GENERATION COLD TECHNOLOGY HA BY SYMATESE CROSS-LINKING HA Typi ca l cross-linking: Heat Syma tese cross-linking: Cold BENEFIT • Cross-linking technol ogy that better preserves the hya l uronic a ci d ch a i n desi gned for dyna mi c p erforma nce a nd effi ca cy • Pot
Slide 4: European Nasolabial Study: Evolysse/Estyme LIFT
European Nasolabial Study: Evolysse /Estyme® LIFT STUDY DESIGN Double blind, ra ndomized, a cti ve control INJECTED VOLUMES LIFT RESTYLANE-L Split fa ce; Lift vs. Restyl a ne-L Vol Mea n: 0.93mL Mea n: 0.95mL N =45 Min, Max 0 .3 0 mL; 2 .0 0 mL 0 .3 0 mL; 2 .0 0 mL Duration 9 months PRIMARY ENDPOINT
Slide 5: European Nasolabial Study: Evolysse/Estyme LIFT
European Nasolabial Study: Evolysse /Estyme® LIFT NASOLABIAL SEVERITY GLOBAL AESTHETIC IMPROVEMENT ≥1 PO I NT I MPRO VEMENT B Y I NVESTI GATO R ASSESSMENT I NVESTI GATO R ASSESSMENT PATI ENT ASSESSMENT Lift Re s t ylan e-L Lift Re s t ylan e-L 100.0% 100.0% 100.0% 100.0% 97.8% 97.7% 100 .0 % 9 5 . 6
Slide 6: European Perioral Fine Line Study: Evolysse/Estyme SMOOTH
European Perioral Fine Line Study: MEAN GRADE CHANGE, FINE LINE SEVERITY SCORE Evolysse /Estyme® SMOOTH 1.8 1.6 1.6 1.5 STUDY DESIGN 1.4 1.3 1.2 Prospective, si n gle arm, n o control, multi- 1.2 center 1 1 N=61 0.8 Duration 12 months 0.6 Avera ge volume injected: 0.5mL • N o touch ups 0.4 0.2 0 0 1
Slide 7: European Mid Face Volume Study: Evolysse/Estyme SCULPT
European Mid Face Volume 3D CHEEK VOLUMETRIC CHANGE FROM BASELINE (mL) Study: Evolysse /Estyme® R i g h t Ch eek Le f t Ch e ek 2 1.9 SCULPT 1.8 1.7 1.8 1.6 1.4 1.3 1.3 1.3 STUDY DESIGN 1.2 1.2 1.2 Prospective, n o control, si n gl e center 1 1.1 1.1 N =60 0.8 0.6 Duration 18 months 0.4 0.2 0 0 1 3
Slide 8: European Lips Study: Evolysse/Estyme LIPS
MEAN GRADE CHANGE FROM BASELINE IN LIP FULLNESS European Lips Study: Lips Em e r vel L ips/ Re s t ylan e Evolysse /Estyme® LIPS K ys se 1.4 1.3 1.3 1.2 1.2 1 0.9 STUDY DESIGN 1.1 1 0.8 0.7 0.8 Prospective, si n gl e arm, multi-center 0.6 0.4 N=72 pa tients 0.2 Duration 12 months 0 0 1 3 6 9 12 MON
Slide 9: European Lips Study: Evolysse/Estyme LIPS
European Lips Study: Evolysse /Estyme® LIPS GLOBAL AESTHETIC SCORE 100% 100% 100% 96% 97% 97% I n vesti gator Pa ti ent 93% 93% 100% 88% 82% 80% 60% 40% 20% 0% 1 3 6 9 12 MON TH S BASELINE DAY 30 MONTH 6 MONTH 12 8
Slide 10: Portfolio of Brands
Portfolio of Brands JEUVEAU® • Pra botulinumtoxin A-xvfs injection EVOLYSSE US 5 Indications • 2 in 2025 (Smooth, Lift) 1 • 1in 2026 (Sculpt) 1 • 2 in 2027 (Eyes, Lips) 1 ESTYME® EU 5 Indi cations in 2H 2024 2 • Smooth (NLF, Perioral Fine Lines) • Lift (NLF) • Scul pt (Mid F a c e Volume) • Li ps (L